FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Guy Griebel

Research Profile

Living Beings

Chemicals & Drugs

Activities & Behaviors

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Guy Griebel; Agnès Jacquet; Christian Laufrais; Richard Alonso; Patrick Avenet; Sandra BEESKE; Michel Decobert; Dominique Françon
Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.
Carine Dournes; Sandra BEESKE; Catherine Belzung; Guy Griebel
Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.
Guy Griebel; Sandra BEESKE; Stephen M Stahl
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Guy Griebel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Guy Griebel; Agnès Jacquet; Christian Laufrais; Richard Alonso; Patrick Avenet; Sandra BEESKE; Michel Decobert; Dominique Françon
Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.
Neuropharmacology 2013;70():19-26.
2013: Carine Dournes; Sandra BEESKE; Catherine Belzung; Guy Griebel
Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543.
Progress in neuro-psychopharmacology & biological psychiatry 2013;40():213-20.
2012: Guy Griebel; Sandra BEESKE; Stephen M Stahl
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
The Journal of clinical psychiatry 2012;73(11):1403-11.
2012: Guy Griebel; Michal Arad; Segev Barak; Sandra BEESKE; Mark Black; Antonio Castro; Amaya De Levie; Elisabeth Genet; Mati Lopez-Grancha; Philippe Pichat; Marie-Pierre Pruniaux; Juan Antonio Sánchez; Jean-Paul Terranova; Geoffrey B Varty; Ina Weiner; Etienne Guillot
SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents.
Pharmacology, biochemistry, and behavior 2012;102(2):203-14.
2011: Alexandre Urani; Julie Philbert; Caroline Cohen; Guy Griebel
The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.
Pharmacology, biochemistry, and behavior 2011;98(3):425-31.
2010: Karina Genaro Borelli; Erwin B Defensor; D Caroline Blanchard; Robert J Blanchard; Guy Griebel
Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery.
Neuroscience letters 2010;485(3):241-5.
2010: David H Overstreet; V M Naimoli; Guy Griebel
Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression.
Pharmacology, biochemistry, and behavior 2010;96(2):206-10.
2010: Jeanne Stemmelin; Caroline Cohen; Ipek Yalcin; Peter Keane; Guy Griebel
Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress.
Behavioural brain research 2010;206(2):310-2.
2010: Denis Boulay; Olivier Bergis; Patrick Avenet; Guy Griebel
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(2):416-27.
2009: Alexandre Surget; Yingjie Wang; Samuel Leman; Yadira Ibarguen-Vargas; Nicole Edgar; Guy Griebel; Catherine Belzung; Etienne Sibille
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(6):1363-80.
2008: Denis Boulay; Philippe Pichat; Gihad Dargazanli; Genevieve Estenne-Bouhtou; Jean Paul Terranova; Nancy Rogacki; Jeanne Stemmelin; Annick Coste; Christophe Lanneau; Christophe Desvignes; Caroline Cohen; Richard Alonso; Xavier Vigé; Bruno Biton; Régis Steinberg; Mireille Sevrin; Florence Oury-Donat; Pascal Guy GEORGE; Olivier Bergis; Guy Griebel; Patrick Avenet; Bernard Scatton
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Pharmacology, biochemistry, and behavior 2008;91(1):47-58.
2008: Alexandre Surget; Michael Saxe; Samuel Leman; Yadira Ibarguen-Vargas; Sylvie Chalon; Guy Griebel; René Hen; Catherine Belzung
Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.
Biological psychiatry 2008;64(4):293-301.
2008: David H Overstreet; Jeanne Stemmelin; Guy Griebel
Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression.
Pharmacology, biochemistry, and behavior 2008;89(4):623-6.
2008: Caroline Louis; Jeanne Stemmelin; Denis Boulay; Olivier E Bergis; Caroline Cohen; Guy Griebel
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models.
Pharmacology, biochemistry, and behavior 2008;89(1):36-45.
2008: Jeanne Stemmelin; Caroline Cohen; Jean-Paul Terranova; Matilde Lopez-Grancha; Philippe Pichat; Olivier E Bergis; Michel Decobert; Vincent Santucci; Dominique Françon; Richard Alonso; Stephen M Stahl; Peter Keane; Patrick Avenet; Bernard Scatton; Gérard Le-Fur; Guy Griebel
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(3):574-87.
2007: Ercem Kodas; C Cohen; C Louis; Guy Griebel
Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling.
Psychopharmacology 2007;194(2):161-71.
2007: Bruno Biton; Olivier E Bergis; Frédéric Galli; Alain Nedelec; Alistair W Lochead; Samir Jegham; Danielle Godet; Christophe Lanneau; Raphaël Santamaria; Françoise Chesney; Jacques Léonardon; Patrick Granger; Marc W Debono; Georg Andrees Bohme; Frédéric Sgard; Francois Besnard; David Graham; Annick Coste; André Oblin; Olivier Curet; Xavier Vigé; Corinne Voltz; Liliane Rouquier; Josiane Souilhac; Vincent Santucci; Christiane Gueudet; Dominique Françon; Régis Steinberg; Guy Griebel; Florence Oury-Donat; Pascal Guy GEORGE; Patrick Avenet; Bernard Scatton
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(1):1-16.
2007: Philippe Pichat; Olivier E Bergis; Jean-Paul Terranova; Alexandre Urani; Christine Duarte; Vincent Santucci; Christiane Gueudet; Carolle Voltz; Régis Steinberg; Jeanne Stemmelin; Florence Oury-Donat; Patrick Avenet; Guy Griebel; Bernard Scatton
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(1):17-34.
2006: Caroline Louis; Caroline Cohen; Ronan Depoortère; Guy Griebel
Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(10):2180-7.
2006: N Salomé; Jeanne Stemmelin; C Cohen; Guy Griebel
Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.
Psychopharmacology 2006;187(2):237-44.
2006: N Salomé; Jeanne Stemmelin; C Cohen; Guy Griebel
Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils.
Pharmacology, biochemistry, and behavior 2006;83(4):533-9.
2006: Catherine Belzung; Ipek Yalcin; Guy Griebel; Alexandre Surget; Samuel Leman
Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.
CNS & neurological disorders drug targets 2006;5(2):135-45.
2006: Wissam El Hage; Guy Griebel; Catherine Belzung
Long-term impaired memory following predatory stress in mice.
Physiology & behavior 2006;87(1):45-50.
2005: Ronan Depoortère; Gihad Dargazanli; Genevieve Estenne-Bouhtou; Annick Coste; Christophe Lanneau; Christophe Desvignes; Martine Poncelet; Michel Heaulme; Vincent Santucci; Michel Decobert; Annie Cudennec; Carolle Voltz; Denis Boulay; Jean-Paul Terranova; Jeanne Stemmelin; Pierre Roger; Benoit Marabout; Mireille Sevrin; Xavier Vigé; Bruno Biton; Régis Steinberg; Dominique Françon; Richard Alonso; Patrick Avenet; Florence Oury-Donat; Ghislaine Perrault; Guy Griebel; Pascal Guy GEORGE; Philippe Soubrié; Bernard Scatton
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(11):1963-85.
2005: Nobuaki Egashira; Akito Tanoue; Fuminori Higashihara; Hiroko Fuchigami; Kazunori Sano; Kenichi Mishima; Yoshihiko Fukue; Hiroshi Nagai; Yukio Takano; Gozoh Tsujimoto; Jeanne Stemmelin; Guy Griebel; Katsunori Iwasaki; Tomoaki Ikeda; Ryoji Nishimura; Michihiro Fujiwara
Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(11):1996-2005.
2005: David H Overstreet; Guy Griebel
Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Pharmacology, biochemistry, and behavior 2005;82(1):223-7.
2005: Jean-Paul Terranova; C Chabot; M-C Barnouin; Ghislaine Perrault; Ronan Depoortere; Guy Griebel; Bernard Scatton
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
Psychopharmacology 2005;181(1):134-44.
2005: Caroline Cohen; Ercem Kodas; Guy Griebel
CB1 receptor antagonists for the treatment of nicotine addiction.
Pharmacology, biochemistry, and behavior 2005;81(2):387-95.
2005: Stephanie C Licata; Donna M Platt; James M Cook; P V V Srirama Sarma; Guy Griebel; James K Rowlett
Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one].
The Journal of pharmacology and experimental therapeutics 2005;313(3):1118-25.
2005: D Caroline Blanchard; Robert J Blanchard; Guy Griebel
Defensive responses to predator threat in the rat and mouse.
Current protocols in neuroscience / editorial board, Jacqueline N. Crawley ... [et al.] 2005;Chapter 8():Unit 8.19.
2005: Guy Griebel; Jeanne Stemmelin; Bernard Scatton
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Biological psychiatry 2005;57(3):261-7.
2005: Guy Griebel; Jeanne Stemmelin; Claudine Serradeil-Le Gal; Philippe Soubrié
Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Current pharmaceutical design 2005;11(12):1549-59.
2005: Claudine Serradeil-Le Gal; Jean Wagnon; Bernard Tonnerre; Richard Roux; Georges Garcia; Guy Griebel; Alain Aulombard
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
CNS drug reviews 2005;11(1):53-68.
2005: Robert J Blanchard; Guy Griebel; Catherine Farrokhi; Chris M Markham; Mu Yang; D Caroline Blanchard
AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters.
Pharmacology, biochemistry, and behavior 2005;80(1):189-94.
2005: Jeanne Stemmelin; Ludovit Lukovic; Nicolas Salome; Guy Griebel
Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(1):35-42.
2005: Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(1):145-55.
2004: David H Overstreet; Guy Griebel
Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
European journal of pharmacology 2004;497(1):49-53.
2004: Denis Boulay; Ronan Depoortère; C Louis; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
Neuropharmacology 2004;46(8):1121-9.
2004: Catherine Farrokhi; D Caroline Blanchard; Guy Griebel; Mu Yang; Coty Gonzales; Chris M Markham; Robert J Blanchard
Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters.
Pharmacology, biochemistry, and behavior 2004;77(3):465-9.
2004: Richard Alonso; Guy Griebel; G Pavone; Jeanne Stemmelin; G Le Fur; Philippe Soubrié
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Molecular psychiatry 2004;9(3):278-86, 224.
2004: Wissam El Hage; Sylvie Peronny; Guy Griebel; Catherine Belzung
Impaired memory following predatory stress in mice is improved by fluoxetine.
Progress in neuro-psychopharmacology & biological psychiatry 2004;28(1):123-8.
2003: D Caroline Blanchard; Guy Griebel; Robert J Blanchard
Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(8):1177-85.
2003: Andrew Holmes; Markus Heilig; Nadia M J Rupniak; Thomas Steckler; Guy Griebel
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
Trends in pharmacological sciences 2003;24(11):580-8.
2003: Claudine Serradeil-Le Gal; Sylvain Derick; Gabrielle Brossard; Maurice Manning; Jacques Simiand; Rolf Gaillard; Guy Griebel; Gilles Guillon
Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
Stress (Amsterdam, Netherlands) 2003;6(3):199-206.
2003: Cecile Ducottet; Guy Griebel; Catherine Belzung
Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):625-31.
2003: Guy Griebel; Jacques Simiand; Jeanne Stemmelin; Claudine Serradeil-Le Gal; Régis Steinberg
The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
Current drug targets. CNS and neurological disorders 2003;2(3):191-200.
2003: D Caroline Blanchard; Guy Griebel; Robert J Blanchard
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic.
European journal of pharmacology 2003;463(1-3):97-116.
2003: Guy Griebel; Ghislaine Perrault; Jacques Simiand; Caroline Cohen; Patrick Granger; Henri Depoortere; Dominique Françon; Patrick Avenet; Hans Schoemaker; Yannick Evanno; Mireille Sevrin; Pascal Guy GEORGE; Bernard Scatton
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
CNS drug reviews 2003;9(1):3-20.
2002: Régis Steinberg; Richard Alonso; Liliane Rouquier; Christophe Desvignes; Jean-Claude Michaud; Annie Cudennec; Mireille Jung; Jacques Simiand; Guy Griebel; Xavier Emonds-Alt; Gérard Le-Fur; Philippe Soubrié
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
The Journal of pharmacology and experimental therapeutics 2002;303(3):1180-8.
2002: Guy Griebel; Jacques Simiand; Claudine Serradeil-Le Gal; Jean Wagnon; Marc Pascal; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrie
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(9):6370-5.
2002: Guy Griebel; Jacques Simiand; Régis Steinberg; Mireille Jung; Danielle Gully; Pierre Roger; Michel Geslin; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrié
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
The Journal of pharmacology and experimental therapeutics 2002;301(1):333-45.
2002: Danielle Gully; Michel Geslin; Laurence Serva; Evelyne Fontaine; Pierre Roger; Christine Lair; Valerie Darre; Claudine Marcy; Pierre-Eric Rouby; Jacques Simiand; Josette Guitard; Georgette Gout; Régis Steinberg; Daniel Rodier; Guy Griebel; Philippe Soubrie; Marc Pascal; Rebecca PRUSS; Bernard Scatton; Jean-Pierre Maffrand; Gérard Le-Fur
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.
The Journal of pharmacology and experimental therapeutics 2002;301(1):322-32.
2002: Claudine Serradeil-Le Gal; Jean Wagnon; Jacques Simiand; Guy Griebel; Colette Lacour; Gilles Guillon; Claude Barberis; Gabrielle Brossard; Philippe Soubrié; Dino Nisato; Marc Pascal; Rebecca PRUSS; Bernard Scatton; Jean-Pierre Maffrand; Gérard Le-Fur
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
The Journal of pharmacology and experimental therapeutics 2002;300(3):1122-30.
2001: Guy Griebel; N Moindrot; C Aliaga; Jacques Simiand; Philippe Soubrié
Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.
Neuroscience and biobehavioral reviews 2001;25(7-8):619-26.
2001: Guy Griebel; G Perrault; P Soubrié
Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents.
Psychopharmacology 2001;158(3):241-51.
2001: Catherine Belzung; Guy Griebel
Measuring normal and pathological anxiety-like behaviour in mice: a review.
Behavioural brain research 2001;125(1-2):141-9.
2001: Régis Steinberg; Richard Alonso; Guy Griebel; Lionel Bert; Mireille Jung; Florence Oury-Donat; Martine Poncelet; Christiane Gueudet; Christophe Desvignes; Gérard Le-Fur; Philippe Soubrié
Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.
The Journal of pharmacology and experimental therapeutics 2001;299(2):449-58.
2001: Catherine Belzung; Wissam El Hage; N Moindrot; Guy Griebel
Behavioral and neurochemical changes following predatory stress in mice.
Neuropharmacology 2001;41(3):400-8.
2001: Guy Griebel; Ghislaine Perrault; Jacques Simiand; C Cohen; Patrick Granger; Michel Decobert; Dominique Françon; Patrick Avenet; Henri Depoortere; S Tan; André Oblin; H Schoemaker; Y Evanno; Mireille Sevrin; Pascal Guy GEORGE; Bernard Scatton
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.
The Journal of pharmacology and experimental therapeutics 2001;298(2):753-68.
2001: D Caroline Blanchard; Guy Griebel; Robert J Blanchard
Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic.
Neuroscience and biobehavioral reviews 2001;25(3):205-18.
2001: Roberto Andreatini; C Blanchard; R Blanchard; M L Brandão; Antonio Carobrez; Guy Griebel; F S Guimarães; S L Handley; F Jenck; José Roberto Leite; J Rodgers; Luiz Carlos Schenberg; Claudio Da Cunha; F G Graeff
The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.] 2001;34(2):145-54.
2000: Guy Griebel; R J Rodgers; Ghislaine Perrault; D J Sanger
The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety.
Neuropharmacology 2000;39(10):1848-57.
2000: Catherine Belzung; Anne Marie le Guisquet; Guy Griebel
Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice.
Behavioural pharmacology 2000;11(2):125-31.
2000: Guy Griebel; C Belzung; Ghislaine Perrault; D J Sanger
Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice.
Psychopharmacology 2000;148(2):164-70.
1999: DJ Sanger; Guy Griebel; Ghislaine Perrault; Yves Claustre; H Schoemaker
Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity.
Pharmacology, biochemistry, and behavior 1999;64(2):269-73.
1999: Guy Griebel; Ghislaine Perrault; S Tan; H Schoemaker; DJ Sanger
Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands.
Behavioural pharmacology 1999;10(5):483-95.
1999: Guy Griebel; Ghislaine Perrault; V Letang; Patrick Granger; Patrick Avenet; H Schoemaker; DJ Sanger
New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes.
Psychopharmacology 1999;146(2):205-13.
1999: Guy Griebel; C Cohen; Ghislaine Perrault; D J Sanger
Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats.
Physiology & behavior 1999;67(3):315-20.
1999: Guy Griebel; Ghislaine Perrault; D J Sanger
Orphanin FQ, a novel neuropeptide with anti-stress-like activity.
Brain research 1999;836(1-2):221-4.
1999: Guy Griebel; Ghislaine Perrault; S Tan; H Schoemaker; DJ Sanger
Pharmacological studies on synthetic flavonoids: comparison with diazepam.
Neuropharmacology 1999;38(7):965-77.
1999: Guy Griebel; R J Rodgers; Ghislaine Perrault; DJ Sanger
Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists.
Psychopharmacology 1999;144(2):121-30.
1999: Guy Griebel
Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
Pharmacology & therapeutics 1999;82(1):1-61.
1999: Guy Griebel; Ghislaine Perrault; DJ Sanger
Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice.
Pharmacology, biochemistry, and behavior 1999;62(4):689-94.
1999: Guy Griebel; Ghislaine Perrault; DJ Sanger
Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity.
Progress in neuro-psychopharmacology & biological psychiatry 1999;23(1):81-98.
1998: D Caroline Blanchard; Guy Griebel; R J Rodgers; Robert J Blanchard
Benzodiazepine and serotonergic modulation of antipredator and conspecific defense.
Neuroscience and biobehavioral reviews 1998;22(5):597-612.
1998: Guy Griebel; Olivier Curet; Ghislaine Perrault; DJ Sanger
Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels.
Neuropharmacology 1998;37(7):927-35.
1998: Guy Griebel; Ghislaine Perrault; DJ Sanger
Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone.
Psychopharmacology 1998;138(1):55-66.
1998: Guy Griebel; Ghislaine Perrault; DJ Sanger
Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents.
Journal of psychopharmacology (Oxford, England) 1998;12(4):356-65.
1997: Guy Griebel; Ghislaine Perrault; DJ Sanger
CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours.
Behavioural pharmacology 1997;8(6-7):549-60.
1997: Robert J Blanchard; Guy Griebel; JA Henrie; D Caroline Blanchard
Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries.
Neuroscience and biobehavioral reviews 1997;21(6):783-9.
1997: Robert J Blanchard; Guy Griebel; B Guardiola-Lemaître; M M Brush; J Lee; D Caroline Blanchard
An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome.
Pharmacology, biochemistry, and behavior 1997;57(4):897-908.
1997: Guy Griebel; Robert John Rodgers; Ghislaine Perrault; D J Sanger
Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test.
Pharmacology, biochemistry, and behavior 1997;57(4):817-27.
1997: Guy Griebel; Ghislaine Perrault; DJ Sanger
A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.
Neuropharmacology 1997;36(6):793-802.
1997: Guy Griebel; Ghislaine Perrault; DJ Sanger
Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs.
Psychopharmacology 1997;131(2):180-6.
1996: Guy Griebel; D Caroline Blanchard; R J Blanchard
Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study.
Physiology & behavior 1996;60(5):1255-60.
1996: Guy Griebel; D Caroline Blanchard; Marie-Claire Rettori; B Guardiola-Lemaître; Robert J Blanchard
Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357.
Pharmacology, biochemistry, and behavior 1996;54(2):509-16.
1996: Guy Griebel; DJ Sanger; Ghislaine Perrault
The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.
Psychopharmacology 1996;124(3):245-54.
1996: Guy Griebel
Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story?
Polish journal of pharmacology 1996;48(2):129-36.
1996: Guy Griebel; D Caroline Blanchard; R J Blanchard
Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks.
Progress in neuro-psychopharmacology & biological psychiatry 1996;20(2):185-205.
1996: Guy Griebel; D J Sanger; Ghislaine Perrault
Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety.
Neuropharmacology 1996;35(8):1081-91.
1995: Guy Griebel; D Caroline Blanchard; A Jung; J C Lee; C K Masuda; R J Blanchard
Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam.
Neuropharmacology 1995;34(12):1625-33.
1995: Guy Griebel; D Caroline Blanchard; R S Agnes; Robert J Blanchard
Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine.
Psychopharmacology 1995;120(1):57-66.
1995: Guy Griebel; D Caroline Blanchard; A Jung; C K Masuda; Robert J Blanchard
5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone.
Pharmacology, biochemistry, and behavior 1995;51(2-3):235-44.
1995: Guy Griebel
5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.
Pharmacology & therapeutics 1995;65(3):319-95.
1994: Guy Griebel; Jean-Luc Moreau; François Jenck; René Misslin; James R Martin
Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents.
Psychopharmacology 1994;113(3-4):463-70.
1992: Jean-Luc Moreau; Guy Griebel; François Jenck; James R Martin; U Widmer; W E Haefely
Behavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys.
Brain research bulletin 1992;29(6):901-4.
1992: R Bouchon; Guy Griebel; Emanuel Vogel; René Misslin; P Ropartz
Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice.
Neuroreport 1992;3(2):210-2.
1992: Guy Griebel; René Misslin; M Pawlowski; B Guardiola Lemaître; Gérald Guillaumet; Jean-Guy Bizot-Espiard
Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice.
Neuroreport 1992;3(1):84-6.
1991: Guy Griebel; René Misslin; M Pawlowski; Emanuel Vogel
m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice.
Neuroreport 1991;2(10):627-9.
1991: Guy Griebel; René Misslin; Emanuel Vogel; Jean-Jacques Bourguignon
Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors.
Pharmacology, biochemistry, and behavior 1991;39(2):321-3.
1991: Guy Griebel; René Misslin; Emanuel Vogel
Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice.
Neuroreport 1991;2(3):139-40.
1991: Guy Griebel; M Saffroy-Spittler; René Misslin; D Remmy; Emanuel Vogel; Jean-Jacques Bourguignon
Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX.
Psychopharmacology 1991;103(4):541-4.
1990: René Misslin; Guy Griebel; M Saffroy-Spittler; Emanuel Vogel
Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice.
Neuroreport 1990;1(3-4):267-70.
1990: Guy Griebel; M Saffroy-Spittler; René Misslin; Emanuel Vogel; J R Martin
Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice.
Psychopharmacology 1990;102(4):498-502.